

Influenza Update:

Pharmacist Focus on the Challenges of Early Identification and Timely Treatment

Selected References:

- Centers for Disease Control and Prevention. CDC Seasonal Flu Vaccine Effectiveness Studies. <https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm#figure>. Published July 1, 2020.
- Centers for Disease Control and Prevention. Information for Clinicians on Influenza Virus Testing. <https://www.cdc.gov/flu/professionals/diagnosis/index.htm>. Published August 31, 2020.
- Centers for Disease Control and Prevention. Influenza Antiviral Medications. <https://www.cdc.gov/flu/professionals/antivirals/index.htm>. Published August 31, 2020.
- Centers for Disease Control and Prevention. Influenza Virus Testing Methods. <https://www.cdc.gov/flu/professionals/diagnosis/table-testing-methods.htm>. Published August 10, 2020.
- Centers for Disease Control and Prevention. Overview of Influenza Testing Methods. <https://www.cdc.gov/flu/professionals/diagnosis/overview-testing-methods.htm>. Published August 31, 2020.
- Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2 (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>. Accessed September 1, 2020.
- Centers for Disease Control and Prevention. Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors. <https://www.cdc.gov/flu/professionals/diagnosis/rapidlab.htm>. Published February 4, 2019. Accessed September 3, 2020.
- Centers for Disease Control and Prevention. Similarities and Differences between Flu and COVID-19. <https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm>. Published August 31, 2020. Accessed August 31, 2020.
- Centers for Disease Control and Prevention. Weekly U.S. Influenza Surveillance Report. <https://www.cdc.gov/flu/weekly/index.htm>. Published September 18, 2020.
- Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2020–21 influenza season. *MMWR Recomm Rep*. 2020;69(8):1–24.
- Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. *N Engl J Med*. 2018;379(10):913–23.
- Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. *N Engl J Med*. 2020;383(4):309–20.

Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomized, placebo-controlled, phase 3 trial. *Lancet Infect Dis*. 2020;S1473-3099(20)30004-9.

U.S. Food and Drug Administration. Emergency Use Authorization. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#sarscov2antibody>. Accessed August 31, 2020.

Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. *Clin Infect Dis*. 2019;68(6):e1–47.

Yokoyama T, Sakaguchi H, Ishibashi T, et al. Baloxavir marboxil 2% granules in Japanese children with influenza: an open-label phase 3 study. *Pediatr Infect J*. 2020;39(8):706–12.